Rainbow BioSciences (RBCC) Target Forms Collaboration with Brewer Sports International
Scottsdale 5/07/2012 06:25 PM GMT (WooEB)
QualityStocks would like to highlight Rainbow BioSciences, a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. Rainbow Biosciences is a new company focused on identifying, developing and marketing the next generation of bioscience solutions for the healthcare and scientific communities.
In the company’s news last week,
Rainbow BioSciences LLC announced the newly formed collaboration of its latest acquisition target, Amarantus Biosciences Inc. (AMBS), with Brewer Sports International (BSI). The partnership was established to increase awareness of new medical therapies being developed to treat traumatic brain injuries (TBI) as a result of football and other contact sports.
The newly formed Coalition for Concussion Treatment is complementary to Amarantus’ strategy of developing diagnostic and treatment options for TBI. Part of the coalition’s mission is to educate parents, players, fans, and the sports community on the potential that new advances in developing new treatments can offer for acute symptoms, as well as the potential they carry for reducing the long-term effects of these injuries on the brain.
To increase awareness of these developments and products on a larger scale, the coalition is using social media and has created a viral campaign through Twitter and other digital and social media outlets.
The coalition recently achieved what it calls a “critical milestone” with its Twitter account announcing that 100 people have signed a petition endorsing the movement and seeking to disseminate critical information about promising new therapies that BSI plans to identify and raise awareness for in upcoming months.
Rainbow BioSciences said spreading the word of new advancements in treatments for traumatic brain injury is vital because it allows the broader community to support drug developers’ efforts.
Rainbow BioSciences and Amarantus signed a letter of intent earlier this week.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
Email Article to a friend
Receive alerts for QualityStocks to your inbox.
Sign up for StockFiling Alerts